Community Advisory Board

Readers Rep

Markets:

Overview

News

Currencies

International

Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

14.88 -0.65 (-4.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Schrodinger, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Schrödinger Announces Multi-Target Collaboration and Expanded Software Licensing Agreement with Novartis

November 12, 2024

From Schrödinger

Via Business Wire

Earnings Scheduled For November 12, 2024 ↗

November 12, 2024

Via Benzinga

Schrödinger to Present at Jefferies London Healthcare Conference

November 04, 2024

From Schrödinger

Via Business Wire

Schrödinger to Announce Third Quarter 2024 Financial Results on November 12

October 31, 2024

From Schrödinger

Via Business Wire

What Analysts Are Saying About Schrodinger Stock ↗

July 11, 2024

Via Benzinga

Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC-NCI-AACR Symposium

October 23, 2024

From Schrödinger

Via Business Wire

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

October 17, 2024

From Schrödinger

Via Business Wire

Schrödinger to Present New Preclinical SGR-3515 and PRMT5-MTA Data at 2024 EORTC-NCI-AACR Symposium

October 09, 2024

From Schrödinger

Via Business Wire

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 18, 2024

From Schrödinger

Via Business Wire

AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week ↗

September 15, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 which should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th ↗

September 10, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030 and should result in as many as 50 novel therapies being brought to market by then and generate annual...

Via Talk Markets

Our AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone! ↗

September 05, 2024

The August ISM manufacturing index reported on Tuesday that figures came in below consensus expectation. That raised fears about the strength of the economy, driving down our Our AI-Focused Drug...

Via Talk Markets

Topics Economy

Our AI-Focused Drug Discovery Stocks Portfolio Was Up Almost 7% Last Week ↗

August 27, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% between now and 2030.

Via Talk Markets

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

August 16, 2024

From Schrödinger

Via Business Wire

AI-Focused Drug Discovery Stocks Portfolio Hit Hard: Down 14% MTD ↗

August 14, 2024

The AI-powered drug discovery process is expected to grow by a 30% CAGR between now and 2030 which should result in approximately 50 novel therapies and generate annual sales in excess of $50 billion...

Via Talk Markets

Schrödinger to Present at Morgan Stanley Global Healthcare Conference

August 14, 2024

From Schrödinger

Via Business Wire

The 3 Best Med Tech Stocks to Buy Now ↗

August 05, 2024

Med tech firms are tremendously improving healthcare and making a great deal of money. Here are the three best med tech stocks to buy now.

Via InvestorPlace

SDGR Stock Earnings: Schrodinger Beats EPS, Beats Revenue for Q2 2024 ↗

July 31, 2024

SDGR stock results show that Schrodinger beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Schrödinger Reports Strong Second Quarter 2024 Financial Results

July 31, 2024

From Schrödinger

Via Business Wire

AI-Focused Drug Discovery Stocks Portfolio Up 7% Last Week; Up 19% MTD ↗

July 30, 2024

The AI-powered drug discovery process is expected to grow by a CAGR of 30% by 2030.

Via Talk Markets

3 Small-Cap Stocks to Buy at a 52-Week Low ↗

July 27, 2024

The Russell 2000 is hinting at sector rotation, meaning it’s time for bargain hunters to look for small-cap stocks at 52-week lows

Via InvestorPlace

Schrödinger Launches Initiative to Significantly Expand Application of Computational Tools for Predictive Toxicology

July 26, 2024

From Schrödinger

Via Business Wire

3 Stocks That Could Benefit Big Time From Coming Interest Rate Cuts ↗

July 22, 2024

The Fed is widely expected to cut interest rates a great deal. Here are three stocks to buy to benefit from these interest rate cuts.

Via InvestorPlace

Topics Economy

AI-Powered Drug Discovery Stocks Portfolio Up 14% MTD; Still Down 30% YTD ↗

July 18, 2024

To capitalize on the transition to more AI-focused drug development investors need to understand the drug development process and the financial health and market potential of those companies under...

Via Talk Markets

Schrödinger to Announce Second Quarter 2024 Financial Results on July 31

July 17, 2024

From Schrödinger

Via Business Wire

Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

July 16, 2024

From Schrödinger

Via Business Wire

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

Simulations Plus Stock Drops 15% Despite EPS Beat

July 05, 2024

Simulations Plus fell 15% the day after its earnings release despite beating EPS estimates due to lower margins and lower full-year guidance.

Via MarketBeat

Topics Artificial Intelligence

3 Top-Rated Gene Editing Stocks Actually Making Money ↗

July 03, 2024

Profitable gene editing stocks make increasingly compelling investments as therapies commercialize this year and beyond.

Via InvestorPlace

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

< Previous 1 2 3 4 5 6 7 8 9

...

14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

About Us

Schrodinger, Inc. - Common Stock (NQ:SDGR)

All News about Schrodinger, Inc. - Common Stock